Insulin Glargine Market, By Type (Insulin Glargine) and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Insulin glargine is a long-acting, synthetic version of human insulin. It belongs to a drug class called long-acting insulins. It is a form of medical insulin used to manage type I and type II diabetes. Like other types of insulin, insulin glargine is used to keep blood sugar level close to normal. It works by replacing the insulin that is produced by the body and by helping move sugar from the blood into other body tissues where it is used for the energy. Insulin glargine is FDA approved to treat adults and children with type 1 diabetes and adults with type 2 diabetes. Thus, there is an increase in demand for insulin glargine worldwide.

Market Dynamics:

Increase in prevalence of diabetes, growing geriatric population, increase in number of clinical trials, increase in research and development, and increase in awareness among people are some major factors expected to aid in the growth of the global insulin glargine market.

In January 2022, FDA announced its approval of Rezvoglar (insulin glargine-aglr), a new long-acting basal insulin, for adults and children with type 1 diabetes and adults with type 2 diabetes. Rezvoglar was approved as a biosimilar to Sanofi's Lantus (insulin glargine).

In December 2021, FDA approved a second insulin glargine biosimilar, an Eli Lilly product called Rezvoglar, which references Lantus.

In June 2020, Biocon and Mylan got the U.S. food and drug administration nod to launch for its insulin glargine injection in vial and pre-filled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes.

Key features of the study:

• This report provides in-depth analysis of the global insulin glargine market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global insulin glargine market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation:

• Global Insulin Glargine Market By Type:
  • Insulin Glargine
• Global Insulin Glargine Market By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
• Company Profiles:
  • Julphar
  • Biocon
  • Eli Lilly
  • Sanofi Aventis
  • Novo Nordisk AS